The obesity drug class has evolved through three generations in the last decade. Single agonists like semaglutide target one receptor (GLP-1). Dual agonists like tirzepatide hit two (GLP-1 plus GIP). Triple agonists like retatrutide hit three (GLP-1, GIP, and glucagon). Each generation has produced bigger weight loss numbers than the last.<\/p>\n
The trade-off isn’t only efficacy. More receptors mean more biology in play, which can mean more lean mass loss in some cases, different side-effect profiles, and unknowns that the long-running single-agonist trials have already resolved. There’s also a regulatory gap. Single and dual agonists are FDA-approved. Triple agonists are still in phase 3.<\/p>\n
This guide walks through the three generations using trial-by-trial data, mechanism, and the practical question of which generation a patient should actually choose in 2026.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Single agonists bind only the GLP-1 receptor.<\/strong> This receptor sits on pancreatic beta cells (where it boosts glucose-dependent insulin secretion), in the brain’s appetite centers (where it produces satiety), and along the GI tract (where it slows gastric emptying). FDA-approved single agonists include semaglutide (Ozempic\u00ae, Wegovy\u00ae, Rybelsus\u00ae), liraglutide (Saxenda\u00ae, Victoza\u00ae), dulaglutide (Trulicity\u00ae), and exenatide (Byetta, Bydureon).<\/p>\n Quick Answer: STEP 1 (Wilding et al. 2021 NEJM): semaglutide 2.4 mg, 14.9% weight loss at 68 weeks<\/p>\n Semaglutide is the most prescribed single agonist for both diabetes and obesity. STEP 1 (Wilding et al. 2021 NEJM) established it as the leading single agonist with 14.9% mean weight loss at 68 weeks at the 2.4 mg weekly dose. The SUSTAIN program covered diabetes outcomes with A1C reductions of 1.4 to 1.8 points across SUSTAIN 1 through 7. SELECT (Lincoff et al. 2023 NEJM) added cardiovascular outcome data showing a 20% reduction in major adverse cardiovascular events.<\/p>\n Single agonists also have the deepest long-term safety dataset. Liraglutide has been approved since 2010 for diabetes and 2014 for obesity. Most of the field’s understanding of pancreatitis risk, thyroid C-cell tumor monitoring, and gallbladder events comes from this 15+ years of single-agonist exposure data.<\/p>\n Dual agonists bind both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.<\/strong> Tirzepatide is the only FDA-approved dual agonist (Mounjaro\u00ae for diabetes, Zepbound\u00ae for obesity). GIP is another incretin hormone released by the gut after meals. Its receptor effects on appetite and energy balance were debated for years until tirzepatide’s clinical data settled the question.<\/p>\n SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% mean weight loss at 72 weeks at the 15 mg dose, with 57% of patients hitting 20% or more body weight loss. SURMOUNT-2 (Garvey et al. 2023 Lancet) extended this to obesity with type 2 diabetes, showing 15.7% loss (smaller than non-diabetic patients, but still well above semaglutide in matched populations). The SURPASS program for diabetes showed A1C reductions of 1.9 to 2.6 points, again exceeding single agonists.<\/p>\n The biological hypothesis is that GIP receptor activation works on adipose tissue insulin sensitivity and energy expenditure in ways that complement GLP-1’s appetite effects. Whether GIP is acting as an agonist or a partial antagonist at the receptor is still debated, but the clinical effect is clear.<\/p>\n Triple agonists add a third receptor target: glucagon.<\/strong> Retatrutide is the most advanced triple agonist in clinical trials, targeting GLP-1, GIP, and glucagon. Adding glucagon receptor activity is counterintuitive (glucagon raises blood sugar) but works because the glucagon effect on hepatic energy expenditure outweighs the modest glycemic effect at the doses studied.<\/p>\n The retatrutide phase 2 trial (Jastreboff et al. 2023 NEJM) showed 24.2% mean weight loss at 12 mg over 48 weeks, with a continued slope at the end of the trial suggesting more loss with longer treatment. A subset of patients hit 30% or more body weight loss, approaching bariatric surgery territory.<\/p>\n Phase 3 trials (TRIUMPH program) are running through 2025 and 2026. If results hold, retatrutide could become the first FDA-approved triple agonist, likely in 2026 or 2027.<\/p>\n Side by side at the highest published doses:<\/p>\n Each generation adds roughly 5 to 6 percentage points of mean weight loss. The retatrutide data is from a smaller phase 2 trial (338 patients) and may shift with phase 3, but the trajectory is striking.<\/p>\n Cross-trial comparisons aren’t perfect because patient populations and durations differ. SURMOUNT-5 (2024 NEJM), the first head-to-head trial of tirzepatide versus semaglutide in obesity, showed tirzepatide produced 20.2% loss versus 13.7% for semaglutide at 72 weeks. That confirmed the dual versus single gap was real, not a trial artifact.<\/p>\n GI side effects (nausea, vomiting, diarrhea, constipation) appear at roughly similar rates across all three generations, though severity and pattern shift.<\/strong> Nausea hits 16% to 20% in STEP, 15% to 24% in SURMOUNT, and 12% to 35% in retatrutide phase 2 depending on dose.<\/p>\n Triple agonists add a potential for mild elevations in heart rate and resting metabolic rate due to the glucagon component. The retatrutide phase 2 trial showed heart rate increases averaging 3 to 6 beats per minute, similar to semaglutide and tirzepatide. Modest transient increases in liver enzymes were noted in some retatrutide patients but resolved on continued treatment.<\/p>\n Lean mass loss is one of the active research questions for all three generations. The proportion of weight lost as lean mass appears to be roughly 25% to 30% across all GLP-1 class drugs, which is similar to the lean mass loss seen in any sustained caloric deficit. Whether the triple agonist’s higher total weight loss preserves more lean mass remains to be seen in larger trials.<\/p>\n Key Takeaway: Retatrutide phase 2 (Jastreboff et al. 2023 NEJM): 24.2% mean weight loss at 12 mg over 48 weeks<\/p>\n Single agonists have the deepest outcomes data.<\/strong> SELECT (semaglutide) showed 20% MACE reduction. FLOW (Perkovic et al. 2024 NEJM) showed 24% reduction in kidney disease progression and cardiovascular death in CKD. STEP-HFpEF showed improved heart failure symptoms and weight loss. LEADER (liraglutide) showed 13% MACE reduction in diabetes.<\/p>\n Dual agonists are catching up. SURMOUNT-OSA (2024 NEJM) led to tirzepatide’s FDA approval for obstructive sleep apnea in December 2024. SURPASS-CVOT, the tirzepatide cardiovascular outcomes trial, is reading out in 2025 to 2026. SYNERGY-NASH showed tirzepatide phase 2 efficacy in MASH.<\/p>\n Triple agonists are too early. Phase 3 cardiovascular and kidney outcome trials for retatrutide are planned but not yet running. The mechanistic case for benefit is strong, but the evidence will take years.<\/p>\n If maximum weight loss is the goal and you can wait 2 to 3 years, triple agonists may be the right answer eventually.<\/strong> For now, they’re not available outside clinical trials.<\/p>\n If you want the best FDA-approved option for weight loss in 2026, tirzepatide is it. SURMOUNT-1 and SURMOUNT-5 both establish it as the leader. Compounded tirzepatide through telehealth platforms like TrimRx makes the dual agonist accessible at roughly to per month, well below brand Zepbound.<\/p>\n If you want the deepest safety record, the most cardiovascular outcomes data, or you can’t tolerate tirzepatide, semaglutide is still excellent. Compounded semaglutide runs to per month, the cheapest entry point to the class.<\/p>\n If you have advanced kidney disease, semaglutide has the FLOW trial data specifically for CKD. If you have OSA, tirzepatide has the SURMOUNT-OSA approval. These specific indications can drive the choice.<\/p>\n Compounded versions of single (semaglutide) and dual (tirzepatide) agonists are widely available through regulated telehealth in 2026.<\/strong> No compounded triple agonists exist because retatrutide isn’t FDA-approved, and compounding outside an FDA-approved reference product is generally not permitted.<\/p>\n A free assessment quiz with TrimRx walks through medical history, weight loss goal, and prior medication response to match patients with the appropriate single or dual agonist. The platform offers a personalized treatment plan that includes dose titration and clinical monitoring.<\/p>\n Beyond retatrutide, the next wave includes oral non-peptide GLP-1s (orforglipron from Lilly), longer-acting once-monthly injections, amylin co-agonists (CagriSema from Novo Nordisk, combining cagrilintide with semaglutide), and selective GLP-1\/glucagon dual agonists like survodutide (Boehringer Ingelheim).<\/strong><\/p>\n CagriSema phase 3 REDEFINE-1 data (2024) showed 22.7% mean weight loss at 68 weeks, putting it in the dual-agonist tier with a different mechanism. Survodutide phase 2 data showed similar numbers. The competitive field is expanding fast, which is good news for patients paying out of pocket as prices come down with competition.<\/p>\n Bottom line: Only single (semaglutide, liraglutide) and dual (tirzepatide) agonists are FDA-approved for obesity in 2026<\/p>\n Not automatically. Each added receptor brings potential side effects along with potential benefits. The phase 2 retatrutide data is impressive but represents one moderately sized trial. Phase 3 will determine whether the higher weight loss comes with manageable safety. The history of obesity drugs is full of compounds that looked great in phase 2 and disappointed later.<\/p>\n It’s still in phase 3 trials. The TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 trials are the key studies for FDA submission. Results are expected in 2025 to 2026 with FDA approval likely in 2026 to 2027 if data holds. Compounding is not permitted for drugs that lack an FDA-approved reference.<\/p>\n Yes, with prescriber guidance. The common protocol is to wait at least one full week after your last semaglutide dose, then start tirzepatide at 2.5 mg weekly and titrate up. There’s no direct dose conversion because the two drugs hit different receptors.<\/p>\n The clinical data says yes, though the receptor pharmacology is debated. Tirzepatide outperforms semaglutide head-to-head (SURMOUNT-5), and isolated GIP receptor agonists in mice and early human studies show modest weight effects. Whether GIP is acting as an agonist or a biased partial antagonist at the receptor in humans is an active research question.<\/p>\n Probably not entirely, especially at first. New drugs typically launch at high brand prices, and compounded versions take years to follow. Tirzepatide has years of safety and outcomes data accumulating. Triple agonists will likely take the highest-need patients first while dual and single agonists remain the dominant prescriptions for several years.<\/p>\n No FDA-approved triple agonists exist as of mid-2026. Retatrutide is the most advanced candidate. Any product marketed online as a triple agonist outside a clinical trial setting is not legitimate and should be avoided.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The obesity drug class has evolved through three generations in the last decade. Single agonists like semaglutide target one receptor (GLP-1).<\/p>\n","protected":false},"author":11,"featured_media":93353,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Single Agonist vs Dual Agonist vs Triple Agonist: Which Generation of Obesity Drug?","_yoast_wpseo_metadesc":"The obesity drug class has evolved through three generations in the last decade. Single agonists like semaglutide target one receptor (GLP-1).","_yoast_wpseo_focuskw":"single dual","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[21,37],"class_list":["post-90651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss","tag-comparisons","tag-obesity"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90651"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90651\/revisions"}],"predecessor-version":[{"id":91877,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90651\/revisions\/91877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93353"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What’s a Dual Agonist?<\/h2>\n
What’s a Triple Agonist?<\/h2>\n
How Do the Weight Loss Numbers Actually Compare?<\/h2>\n
\n
What About Side Effects Across the Three Generations?<\/h2>\n
What Does Each Generation Do for Cardiometabolic Health Beyond Weight?<\/h2>\n
Which Generation Should a Patient Actually Choose?<\/h2>\n
How Do Telehealth Platforms Fit Into the Generation Question?<\/h2>\n
What’s Coming Next?<\/h2>\n
FAQ<\/h2>\n
Is More Receptor Activity Always Better?<\/h3>\n
Why Isn’t Retatrutide Available Yet?<\/h3>\n
Can I Switch From Semaglutide to Tirzepatide?<\/h3>\n
Does GIP Actually Help Weight Loss?<\/h3>\n
Will Triple Agonists Replace Tirzepatide If They’re Approved?<\/h3>\n
Are There Triple Agonists Already on the Market?<\/h3>\n